News on the Role of Antidepressants in and for COVID-19 and Long
                    COVID

Udo Bonnet; Georg Juckel

doi:10.1055/a-2381-2117

Pharmacopsychiatry, Table of Contents

Pharmacopsychiatry 2025; 58(01): 41-44
DOI: 10.1055/a-2381-2117

Letter to the Editor

News on the Role of Antidepressants in and for COVID-19 and Long COVID

Udo Bonnet

¹Department of Mental Health, Evangelisches Krankenhaus Castrop-Rauxel, Academic Teaching Hospital of the University of Duisburg-Essen, Castrop-Rauxel, Germany

²Department of Psychiatry and Psychotherapy, Faculty of Medicine, Landschaftsverband Rheinland-Hospital Essen, University of Duisburg-Essen, Essen, Germany

,

Georg Juckel

³Department of Psychiatry, Psychotherapy and Preventive Medicine, LWL University Hospital, Ruhr University Bochum, Bochum, Germany

› Author Affiliations

Abstract

Full Text

References

References
1 World Health Organization. 2024 accessed 20 May, 2024; https://www.who.int/europe/de/emergencies/overview/16-01-2024-covid-19-vaccinations-have-saved-more-than-1.4-million-lives-in-the-who-european-region--a-new-study-finds
2 Robert Koch Institut. STIKO: Aktualisierung der COVID-19-Impfempfehlung Epidemiologisches Bulletin. 2024 2. accessed 21 August, 2024; href="https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2024/Ausgaben/02_24.html">https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2024/Ausgaben/02_24.html
3 Xie Y, Choi T, Al-Aly Z. Mortality in patients hospitalized for COVID-19 vs influenza in fall-winter 2023–2024. JAMA 2024; 331: 1963-1965
4 Hoertel N, Sánchez-Rico M, Cougoule C. et al. Repurposing antidepressants inhibiting the sphingomyelinase acid/ceramide system against COVID-19: Current evidence and potential mechanisms. Mol Psychiatry 2021; 26: 7098-7099
5 Bonnet U, Juckel G. COVID-19 outcomes: Does the use of psychotropic drugs make a difference? Accumulating evidence of a beneficial effect of antidepressants-A scoping review. J Clin Psychopharmacol 2022; 42: 284-292
6 Mueller JK, Riederer P, Müller WE. Neuropsychiatric drugs against COVID-19: What is the clinical evidence?. Pharmacopsychiatry 2022; 55: 7-15
7 Mueller JK, Ahrens KF, Bauer M. et al. Prevalence of COVID-19 and psychotropic drug treatment in psychiatric in-patients in Germany in 2020: Results from a nationwide pilot survey. Pharmacopsychiatry 2023; 56: 227-238
8 Bonnet U, Juckel G, Scherbaum N. et al. Are persons treated with antidepressants and/or antipsychotics possibly better protected against severe COVID 19?. Pharmacopsychiatry 2021; 54: 142-143
9 Wen W, Chen C, Tang J. et al. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19: A meta-analysis. Ann Med 2022; 54: 516-523
10 Frontera JA, Thorpe LE, Simon NM. et al. Post-acute sequelae of COVID-19 symptom phenotypes and therapeutic strategies: A prospective, observational study. PLoS One 2022; 17: e0275274
11 Wannigamnah DL, Hurst C, Phattharapornjaroen P. et al. Early treatment with fluvoxamine, bromhexine, cyproheptadine, and niclosamide to prevent clinical deterioration in patients with symptomatic COVID-19: A randomized clinical trial. EClinicalMedicine 2024; 70: 102517
12 Bonnet U, Juckel G, Kuhn J. Antidepressants for prevention of severe COVID-19, long COVID and outlook for other viral diseases. Front Med 2024; 11: 1305184